title: Lung cancer management in 2010.
abstract: The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.
authors.affiliation: VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA. aganti@unmc.edu
authors.forename: Apar Kishor
authors.initials: AK
authors.lastname: Ganti
authors.forename: Chao H
authors.initials: CH
authors.lastname: Huang
authors.forename: Mark A
authors.initials: MA
authors.lastname: Klein
authors.forename: Sean
authors.initials: S
authors.lastname: Keefe
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Kelley
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy; D018288:Carcinoma, Small Cell / Q000628:therapy; D055088:Early Detection of Cancer; D066246:ErbB Receptors / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D009154:Mutation; D009367:Neoplasm Staging; D010166:Palliative Care
chemical_list: D066246:ErbB Receptors